INmune Bio Reveals Anticipated Findings from MINDFuL Trial
INmune Bio Inc. Announces Upcoming Conference Call for MINDFuL Trial Results
On Monday, a significant event awaits as INmune Bio Inc. (NASDAQ: INMB), a pioneering clinical-stage company focused on inflammation and immunology, prepares to share insights from the Phase 2 MINDFuL trial, aimed at early Alzheimer’s Disease. This call will start at 8:00 AM EDT.
Overview of the Conference Call
The dedicated team at INmune Bio is eager to share the top line results from this important study. Interested participants should aim to join the call around 10 minutes prior to the start time. When connecting, participants can ask for the INmune Bio MINDFuL Conference Call to reach the operator.
Details for the Call
The conference call will transpire on the following details:
Date: Expected soon
Time: 8:00 AM Eastern Time
Participant Dial-in Numbers:
- US Dial-in: +1-800-267-6316
- International Dial-in: +1-203-518-9783
To ensure easy access, a designated conference ID, INMUNE, will be necessary for entry.
About the MINDFuL Clinical Trial
The MINDFuL trial, under the identifier NCT05318976, stands as a pivotal international, blinded, and randomized study focusing on patients diagnosed with Early Alzheimer’s Disease (AD). More specifically, it targets individuals exhibiting mild cognitive impairment (MCI) and early-stage AD, characterized by elevated neuroinflammation biomarkers. These include elevated C-reactive protein (CRP), hemoglobin A1c (HgbA1c), erythrocyte sedimentation rate (ESR), or the presence of the ApoE4 allele.
Study Parameters and Objective
Pioneering the study, patients are administered either the investigational therapy, XPro™, or a placebo at a ratio of 2:1 over a six-month timeline. The primary cognitive assessments will focus on the EMACC and CDR metrics, with participants receiving XPro™ via a simple once-a-week subcutaneous injection.
Understanding XPro™ and Its Impact
XPro™ represents an innovative next-generation inhibitor of tumor necrosis factor (TNF). Diverging from traditional TNF inhibitors, it selectively neutralizes soluble TNF (sTNF), leaving trans-membrane TNF (tmTNF) intact. This unique action is anticipated to yield noteworthy benefits for patients contending with neurologic diseases, particularly by diminishing neuroinflammation.
To grasp the crucial nature of targeting neuroinflammation for enhancing cognitive abilities and rekindling neuronal communication, more information can be found on INmune’s dedicated resources.
The Mission of INmune Bio Inc.
INmune Bio Inc. is a publicly traded clinical-stage biotechnology entity focused on harnessing the innate immune system for combatting diseases. Their innovative capabilities include three distinct product platforms:
- The Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform aims to neutralize soluble TNF, addressing innate immune dysfunction linked to numerous disorders. Clinical trials are underway to evaluate the therapeutic potential for Mild Alzheimer’s, Mild Cognitive Impairment, and treatment-resistant depression.
- The Natural Killer Cell Priming Platform boasts INKmune®, designed to empower patients’ NK cells against lingering cancer, with ongoing trials in metastatic castration-resistant prostate cancer.
- The CORDStrom™ program involves a proprietary, pooled collection of human umbilical cord-derived mesenchymal stromal/stem cells, recently completing a randomized trial focussing on recessive dystrophic epidermolysis bullosa.
Utilizing a precision medicine approach, INmune Bio aims to transform treatment outcomes for chronic inflammation-driven diseases and cancer. For further insights about their offerings or to learn more about their research initiatives, visiting their official website can provide valuable information.
Frequently Asked Questions
What is the MINDFuL trial?
The MINDFuL trial is a Phase 2 clinical study that investigates XPro™'s effects on patients with early-stage Alzheimer’s Disease.
When will the trial results be available?
INmune Bio is set to announce results during a conference call on a Monday morning very soon.
What is XPro™?
XPro™ is an innovative treatment aimed at neutralizing specific types of tumor necrosis factor to address neuroinflammation.
What conditions does INmune Bio focus on?
INmune Bio primarily targets diseases linked to the innate immune system, including Alzheimer’s disease, cancer, and chronic inflammatory disorders.
How can I participate in the conference call?
To join, simply dial the participant numbers provided about 10 minutes before the call begins.
About The Author
Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
